Evidence map›Paper›PMID 28744814›Full record

Trial reportMolecular and cellular biochemistry2018

Arg913Gln of SLC12A3 gene promotes development and progression of end-stage renal disease in Chinese type 2 diabetes mellitus.

Rong Zhang, Langen Zhuang, Ming Li, Juan Zhang, Weijing Zhao, Xiaoxu Ge, Yating Chen, Feng Wang, Niansong Wang, Yuqian Bao and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Molecular and cellular biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Frontiers in medicine · 2022
    Article
  4. Genetic and Biological Effects ofFrontiers in genetics · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. The Susceptibility Genes in Diabetic Nephropathy.Kidney diseases (Basel, Switzerland) · 2018
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Rong ZhangShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Langen ZhuangDepartment of Endocrinology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, Anhui, China.
Ming LiShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Juan ZhangShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Weijing ZhaoShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Xiaoxu GeShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Yating ChenShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Feng WangDepartment of Nephrology, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Niansong WangDepartment of Nephrology, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Yuqian BaoShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Limei LiuShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China. lmliu@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-1570-4786
Yanjun LiuDivision of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Sciences, University of California Los Angeles (UCLA) School of Medicine, Los Angeles, CA, USA.
Weiping JiaShanghai Key Laboratory of Diabetes, Department of Endocrinology & Metabolism, Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Shanghai Sixth People's Hospital · CNFirst Affiliated Hospital of Bengbu Medical College · CNUniversity of California, Los Angeles · US

Funding

The Role of Adipose H6PDH in Type 2 Diabetes and ObesitySC1DK104821 · NIDDK · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI LIU, YANJUN · 2014 to 2017
$1.3M
National Institute of Diabetes and Digestive and Kidney Diseases Grant SC1DK104821Program of Education Research from Shanghai Jiaotong University of Medicine YB150612Project of National Natural Science Foundation of China 81471012, 81270876, 30771022 and 30971384Shanghai Leading Talent SLJ15055
6 · The paper itself

Abstract

Whether the Arg913Gln variation (rs11643718, G/A) of SLC12A3 contributes to diabetic nephropathy (DN) remains controversial. We undertook a case-control study to evaluate the association of the SLC12A3-Arg913Gln variation with the risk of end-stage renal disease (ESRD) in Chinese type 2 diabetes mellitus (T2DM) patients undergoing hemodialysis, and analyzed the genotype-phenotype interaction. Unrelated Chinese T2DM patients (n = 372) with diabetic retinopathy were classified into the non-DN (control) group (n = 151; duration of T2DM >15 years, no signs of renal involvement) and the DN-ESRD group (n = 221; ESRD due to T2DM, receiving hemodialysis). Polymerase chain reaction-direct sequencing was used to genotype the SLC12A3-Arg913Gln variation for all participants. The frequency of the GA+AA genotype in the DN-ESRD group was significantly higher than that of the non-DN group (23.1 vs. 9.9%; adjusted OR 2.2 (95% CI 1.3-4.5), P = 0.019). In the non-DN group, GA+AA carriers had a significantly higher urinary albumin excretion rate (UAER) and diastolic blood pressure compared with GG carriers (both P < 0.05). The SLC12A3-Arg913Gln variation may be associated with increased blood pressure and UAER and, therefore, could be used to predict the development and progression of DN-ESRD in Chinese T2DM patients undergoing hemodialysis.

Indexed as

Mutation, MissenseAgedAmino Acid SubstitutionAsian PeopleChinaDiabetes Mellitus, Type 2Diabetic NephropathiesGenotypeHumansKidney Failure, ChronicMiddle AgedRenal DialysisSolute Carrier Family 12, Member 3SLC12A3 protein, humanSolute Carrier Family 12, Member 3Arg913Gln variationEnd-stage renal disease (ESRD)SLC12A3Type-2 diabetes mellitus (T2DM)

Identifiers

PMID28744814
OpenAlexW2736374890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.